Linezolid Accord

Linezolid, the active ingredient in Linezolid Accord, is an oxazolidinone presented as a sterile injection for intravenous use. It is indicated for the treatment of serious bacterial infections, including skin and soft tissue infections, community‑acquired bacterial pneumonia, and nosocomial pneumonia, primarily in adult patients.

GNH USA supplies Linezolid Accord as a licensed, GDP‑compliant international pharmaceutical product, providing reliable access to hospitals, pharmacies and clinics worldwide. The injection conforms to EU regulatory standards and is sourced from approved manufacturing facilities.

Linezolid is an oxazolidinone antibiotic used to treat infections caused by Gram‑positive bacteria.

- Skin and soft tissue infections: effective against MRSA and other resistant Gram‑positive pathogens, leading to clinical cure. - Community‑acquired bacterial pneumonia: provides bacterial eradication and improvement of respiratory symptoms. - Nosocomial pneumonia: used for hospital‑acquired pneumonia caused by susceptible organisms, reducing mortality risk.

Linezolid may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Vomiting: occasional emesis. - Metallic taste: altered taste perception. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count, requiring monitoring. - Anemia: reduction in red blood cell count, potentially leading to fatigue. - Peripheral neuropathy: nerve damage causing tingling or numbness. - Serotonin syndrome: risk when combined with serotonergic agents. - Lactic acidosis: rare metabolic disturbance. - Optic neuritis: vision changes requiring urgent assessment.

Before initiating therapy, consider patient‑specific factors and monitor appropriately.

- Renal impairment: adjust therapy based on renal function and monitor serum creatinine. - Hepatic impairment: monitor liver enzymes during treatment. - Concurrent MAO inhibitors: avoid due to risk of serotonin syndrome. - Long‑term therapy (>2 weeks): regularly monitor complete blood counts. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - SSRIs and SNRIs: risk of serotonin syndrome. - MAO inhibitors: risk of serotonin syndrome. - Rifampicin: significant reduction in linezolid exposure.

Moderate Interactions (Monitor Closely): - Warfarin: may increase anticoagulant effect; monitor INR. - NSAIDs: increased bleeding risk; observe for gastrointestinal events.